Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$12.1B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $12 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in mental health and pain management.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, missing estimates by 48%. Despite this, the stock rose by 8.31% the following day, suggesting some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Axsome's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors will be closely watching for any signs of improvement in earnings and revenue.

Bull Case

If Axsome can show a significant reduction in losses and strong revenue growth, it may indicate that its products are gaining traction in the market.

Bear Case

Conversely, if the company reports wider losses or disappointing sales, it could raise concerns about its long-term viability and lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be, and how does it compare to previous quarters?

Given the company's history of EPS misses, this figure will be crucial in assessing financial health and investor sentiment.

What updates can management provide on product sales and R&D progress?

Insights into sales performance and ongoing research will be key indicators of the company's future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Axsome's potential for recovery, especially given its recent stock performance despite poor earnings.

Supporting Evidence

The stock rose 8.31% after a significant EPS miss, indicating underlying investor optimism.

Options pricing suggests a larger move than historical averages, hinting at potential volatility that could favor a rebound.

Key Risk

If EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Axsome can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would indicate improving financial health.

Bear Confirmed If

An EPS loss greater than -$1.50 would raise concerns about the company's operational efficiency.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around +2.93%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react moderately, reflecting investor caution.

Miss

A miss could lead to a decline of around +1.28%, indicating ongoing concerns about the company's financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of key product launches.
2Updates on R&D spending and future pipeline developments.
3Insights into market demand for existing products.
4Management's outlook on competitive pressures in the pharmaceutical sector.
5Any changes in guidance or strategic direction for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1 2026, Axsome reported an EPS of -$1.26, missing estimates by 48%. Despite this, the stock rose by 8.31% the following day, suggesting some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Axsome can show a significant reduction in losses and strong revenue growth, it may indicate that its products are gaining traction in the market.

Bear Case

Conversely, if the company reports wider losses or disappointing sales, it could raise concerns about its long-term viability and lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be, and how does it compare to previous quarters?

Given the company's history of EPS misses, this figure will be crucial in assessing financial health and investor sentiment.

What updates can management provide on product sales and R&D progress?

Insights into sales performance and ongoing research will be key indicators of the company's future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Axsome's potential for recovery, especially given its recent stock performance despite poor earnings.

Supporting Evidence

The stock rose 8.31% after a significant EPS miss, indicating underlying investor optimism.

Options pricing suggests a larger move than historical averages, hinting at potential volatility that could favor a rebound.

Key Risk

If EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Axsome can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would indicate improving financial health.

Bear Confirmed If

An EPS loss greater than -$1.50 would raise concerns about the company's operational efficiency.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around +2.93%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react moderately, reflecting investor caution.

Miss

A miss could lead to a decline of around +1.28%, indicating ongoing concerns about the company's financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the progress of key product launches.
2Updates on R&D spending and future pipeline developments.
3Insights into market demand for existing products.
4Management's outlook on competitive pressures in the pharmaceutical sector.
5Any changes in guidance or strategic direction for the upcoming quarters.